Vericel Corp (VCEL):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Vericel Corp (VCEL) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7216
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn domains. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. The company is also developing ixmyelocel-T technology, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM). It has manufacturing facilities in Cambridge, Massachusetts; Ann Harbour, Michigan and Kastrup, Denmark. The company sells its products through cell therapy specialists. Vericel is headquartered in Cambridge, the US.

Vericel Corp (VCEL) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vericel Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Vericel Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Vericel Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Vericel Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Vericel Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Vericel Corp, Medical Equipment, Deal Details 10
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 10
Equity Offering 11
Vericel Plans to Raise up to USD200 Million in Public Offering of Securities 11
Vericel Raises USD74.8 Million in Public Offering of Shares 12
Vericel Raises USD19.6 Million in Public Offering of Shares 14
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Vericel Corp – Key Competitors 19
Vericel Corp – Key Employees 20
Vericel Corp – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 06, 2018: Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance 22
May 08, 2018: Vericel Reports First Quarter 2018 Financial Results 24
Mar 05, 2018: Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance 26
Nov 07, 2017: Vericel Reports Third-Quarter 2017 Financial Results 28
Aug 09, 2017: Vericel Reports Second-Quarter 2017 Financial Results 29
May 10, 2017: Vericel Reports First-Quarter 2017 Financial Results 31
Mar 10, 2017: Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results 33
Corporate Communications 35
Aug 20, 2018: Vericel names Jonathan Hopper as chief medical officer 35
Apr 10, 2017: Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Vericel Corp, Medical Equipment, Key Facts, 2017 2
Vericel Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Vericel Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Vericel Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Vericel Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Vericel Corp, Deals By Market, 2012 to YTD 2018 8
Vericel Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 10
Vericel Plans to Raise up to USD200 Million in Public Offering of Securities 11
Vericel Raises USD74.8 Million in Public Offering of Shares 12
Vericel Raises USD19.6 Million in Public Offering of Shares 14
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Vericel Corp, Key Competitors 19
Vericel Corp, Key Employees 20
Vericel Corp, Other Locations 21
Vericel Corp, Subsidiaries 21

List of Figures
Vericel Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Vericel Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Vericel Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Vericel Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Vericel Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Vericel Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Vericel Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Vericel Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Vericel Corp (VCEL):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Natus Medical Incorporated (BABY)-医療機器分野:企業M&A・提携分析
    Summary Natus Medical Incorporated (Natus) is a provider of newborn and neurology healthcare products. Its offers wide range of products for the screening, diagnosis, detection, treatment, monitoring and tracking of ailments in newborn. Natus also offers products for diagnostic hearing assessment in …
  • Evofem Biosciences Inc (EVFM):製薬・医療:M&Aディール及び事業提携情報
    Summary Evofem Biosciences Inc (Evofem) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes reproductive and contraceptive care products for women. The company’s lead product candidate includes Amphora, a non-hormonal vaginal contraceptive gel for the prevention …
  • Insperity, Inc. (NSP):企業の財務・戦略的SWOT分析
    Insperity, Inc. (NSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Kepler Weber S.A. (KEPL3):企業の財務・戦略的SWOT分析
    Kepler Weber S.A. (KEPL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Advanced Digital Broadcast SA:企業の戦略的SWOT分析
    Advanced Digital Broadcast SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • New Hope Corp Ltd:企業の戦略・SWOT・財務情報
    New Hope Corp Ltd - Strategy, SWOT and Corporate Finance Report Summary New Hope Corp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Lycatel Services Limited:企業の戦略的SWOT分析
    Lycatel Services Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Lanka IOC PLC (LIOC.N0000):企業の財務・戦略的SWOT分析
    Summary Lanka IOC Plc (LIOC), a subsidiary of Indian Oil Corporation Ltd is an oil and gas company that imports, sells and distributes petroleum products. The company's products include lubricants, fuels, bitumen and bunkering products. It provides automotive lubricants, including passenger car, die …
  • Omnicell Inc (OMCL):企業の財務・戦略的SWOT分析
    Omnicell Inc (OMCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • US Foods Holding Corp (USFD):企業の財務・戦略的SWOT分析
    US Foods Holding Corp (USFD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Shopper’s Stop Ltd.:戦略・SWOT・企業財務分析
    Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • RayBiotech Inc-製薬・医療分野:企業M&A・提携分析
    Summary RayBiotech Inc (RayBiotech) is a life science company that offers proteins, antibodies and immunological kits. The company’s products include antibody arrays, elisa, functional assays, antibodies and custom recombinant protein service. It provides services such as testing services, custom se …
  • Fortis Inc (FTS):石油・ガス:M&Aディール及び事業提携情報
    Summary Fortis Inc (Fortis) is an oil and gas company that provides development of assets and market capitalization programs. The company offers measurement and monitoring of environmental impacts. It also provides capital program and growth plans to meet the energy needs. Fortis support and partici …
  • Ultra Petroleum Corp.:企業の戦略・SWOT・財務情報
    Ultra Petroleum Corp. - Strategy, SWOT and Corporate Finance Report Summary Ultra Petroleum Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • VeriSign Inc (VRSN):企業の財務・戦略的SWOT分析
    VeriSign Inc (VRSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Institute of Cancer Research-製薬・医療分野:企業M&A・提携分析
    Summary Institute of Cancer Research (ICR), a subsidiary of University of London is a research institute that offers cancer research and education programs. The institute conducts research and develops new therapies for the treatment of cancer including breast and lung cancer. It offers various post …
  • PledPharma AB (PLED):企業の財務・戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colore …
  • Velan Inc (VLN):企業の財務・戦略的SWOT分析
    Velan Inc (VLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Huegli Holding AG:企業の戦略・SWOT・財務情報
    Huegli Holding AG - Strategy, SWOT and Corporate Finance Report Summary Huegli Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • CaroGen Corp-製薬・医療分野:企業M&A・提携分析
    Summary CaroGen Corp (CaroGen) is a vaccine company that offers platform technology development services. The company develops and commercializes nanoparticle therapeutic vaccines. It utilizes its virus-like vesicle platform technology, a proprietary replication competent to develop nano particle th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆